PubRank

Gerard A Rongen

Author PubWeight™ 54.54‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Ischemic preconditioning in the animal kidney, a systematic review and meta-analysis. PLoS One 2012 1.56
2 High incidence of adverse events in healthy volunteers receiving rifampicin and adjusted doses of lopinavir/ritonavir tablets. AIDS 2008 1.55
3 Glyburide inhibits dipyridamole-induced forearm vasodilation but not adenosine-induced forearm vasodilation. Clin Pharmacol Ther 2004 1.54
4 Acute and long-term cardiovascular effects of coffee: implications for coronary heart disease. Pharmacol Ther 2008 1.46
5 Potential role for adenosine in the pathogenesis of the vascular complications of hyperhomocysteinemia. Cardiovasc Res 2003 1.42
6 Vascular adaptation to deconditioning and the effect of an exercise countermeasure: results of the Berlin Bed Rest study. J Appl Physiol (1985) 2005 1.36
7 Vascular adaptation to 4 wk of deconditioning by unilateral lower limb suspension. Am J Physiol Heart Circ Physiol 2004 1.26
8 The cardioprotective effects of metformin. Curr Opin Lipidol 2011 1.19
9 Enhanced endothelin-1-mediated leg vascular tone in healthy older subjects. J Appl Physiol (1985) 2007 1.15
10 Remote ischaemic preconditioning by brief hind limb ischaemia protects against renal ischaemia-reperfusion injury: the role of adenosine. Nephrol Dial Transplant 2011 1.14
11 Metformin prevents myocardial reperfusion injury by activating the adenosine receptor. J Cardiovasc Pharmacol 2009 1.13
12 Metformin improves survival in intensive care unit patients, but why? Crit Care 2013 1.09
13 Caffeine prevents protection in two human models of ischemic preconditioning. J Am Coll Cardiol 2006 1.03
14 In vivo evidence against a role for adenosine in the exercise pressor reflex in humans. J Appl Physiol (1985) 2005 1.02
15 Upregulation of ecto-5'-nucleotidase by rosuvastatin increases the vasodilator response to ischemia. Hypertension 2010 0.92
16 Aging attenuates the protective effect of ischemic preconditioning against endothelial ischemia-reperfusion injury in humans. Am J Physiol Heart Circ Physiol 2013 0.91
17 Metformin therapy in diabetes: the role of cardioprotection. Curr Atheroscler Rep 2013 0.91
18 A causal role for endothelin-1 in the vascular adaptation to skeletal muscle deconditioning in spinal cord injury. Arterioscler Thromb Vasc Biol 2006 0.90
19 Short-term statin treatment does not prevent ischemia and reperfusion-induced endothelial dysfunction in humans. J Cardiovasc Pharmacol 2012 0.90
20 Preserved contribution of nitric oxide to baseline vascular tone in deconditioned human skeletal muscle. J Physiol 2005 0.89
21 Preserved alpha-adrenergic tone in the leg vascular bed of spinal cord-injured individuals. Circulation 2003 0.89
22 Rosuvastatin increases extracellular adenosine formation in humans in vivo: a new perspective on cardiovascular protection. Arterioscler Thromb Vasc Biol 2009 0.89
23 Oral therapy with dipyridamole limits ischemia-reperfusion injury in humans. Clin Pharmacol Ther 2005 0.88
24 Local and remote ischemic postconditionings have synergistic protective effects on renal ischemia-reperfusion injury. Transplantation 2012 0.88
25 Augmented hyperaemia and reduced tissue injury in response to ischaemia in subjects with the 34C > T variant of the AMPD1 gene. Eur Heart J 2007 0.87
26 The 22G>A polymorphism in the adenosine deaminase gene impairs catalytic function but does not affect reactive hyperaemia in humans in vivo. Pharmacogenet Genomics 2008 0.87
27 Improved resistance to ischemia and reperfusion, but impaired protection by ischemic preconditioning in patients with type 1 diabetes mellitus: a pilot study. Cardiovasc Diabetol 2012 0.87
28 The cardiovascular effects of methylxanthines. Handb Exp Pharmacol 2011 0.87
29 Diannexin protects against renal ischemia reperfusion injury and targets phosphatidylserines in ischemic tissue. PLoS One 2011 0.86
30 Unilateral lower limb suspension can cause deep venous thrombosis. Am J Physiol Regul Integr Comp Physiol 2004 0.86
31 The Dutch model for clinical pharmacology: collaboration between physician- and pharmacist--clinical pharmacologists. Br J Clin Pharmacol 2008 0.85
32 Human in vivo research on the vascular effects of adenosine. Eur J Pharmacol 2008 0.85
33 The effect of adenosine receptor agonists on cytokine release by human mononuclear cells depends on the specific Toll-like receptor subtype used for stimulation. Cytokine 2006 0.85
34 Enhanced cellular adenosine uptake limits adenosine receptor stimulation in patients with hyperhomocysteinemia. Arterioscler Thromb Vasc Biol 2004 0.84
35 Role of endogenous vascular endothelial growth factor in endothelium-dependent vasodilation in humans. Hypertension 2013 0.84
36 Interaction study of the combined use of paroxetine and fosamprenavir-ritonavir in healthy subjects. Antimicrob Agents Chemother 2007 0.84
37 Targeting adenosine receptors in the development of cardiovascular therapeutics. Expert Rev Clin Pharmacol 2012 0.84
38 Angiotensin II contributes to the increased baseline leg vascular resistance in spinal cord-injured individuals. J Hypertens 2010 0.82
39 Acute elevation of plasma non-esterified fatty acids increases pulse wave velocity and induces peripheral vasodilation in humans in vivo. Clin Sci (Lond) 2007 0.82
40 Shortcomings of protocols of drug trials in relation to sponsorship as identified by Research Ethics Committees: analysis of comments raised during ethical review. BMC Med Ethics 2014 0.80
41 Diadenosine pentaphosphate vasodilates the forearm vascular bed: inhibition by theophylline and augmentation by dipyridamole. Clin Pharmacol Ther 2002 0.80
42 Leg blood flow measurements using venous occlusion plethysmography during head-up tilt. Clin Auton Res 2007 0.79
43 The 1976C>T polymorphism in the adenosine A2A receptor gene does not affect the vasodilator response to adenosine in humans in vivo. Pharmacogenet Genomics 2007 0.78
44 Atorvastatin does not affect ischaemia-induced phosphatidylserine exposition in humans in-vivo. J Atheroscler Thromb 2011 0.78
45 The influence of diazepam and midazolam on adenosine-induced forearm vasodilation in humans. J Cardiovasc Pharmacol 2004 0.78
46 Humoral signalling compounds in remote ischaemic preconditioning of the kidney, a role for the opioid receptor. Nephrol Dial Transplant 2013 0.78
47 Endotoxin tolerance does not limit mild ischemia-reperfusion injury in humans in vivo. Innate Immun 2009 0.77
48 Angiotensin II type 1 receptor blockade does not enhance apoptotic cell death during ischemia and reperfusion in humans in vivo. J Cardiovasc Pharmacol 2011 0.77
49 Stress susceptibility as a determinant of the response to adrenergic stimuli in mesenteric resistance arteries of the rat. J Cardiovasc Pharmacol 2002 0.77
50 Stress susceptibility as a determinant of endothelium-dependent vascular reactivity in rat mesenteric arteries. J Cardiovasc Pharmacol 2003 0.77
51 The role of carotid chemoreceptors in the sympathetic activation by adenosine in humans. Clin Sci (Lond) 2004 0.77
52 Rosiglitazone reduces ischaemia-reperfusion injury in patients with the metabolic syndrome. Eur Heart J 2009 0.76
53 Sympathetic nonadrenergic transmission contributes to autonomic dysreflexia in spinal cord-injured individuals. Hypertension 2010 0.76
54 Impaired endothelium-dependent vasodilation does not initiate the development of sunitinib-associated hypertension. J Hypertens 2015 0.76
55 Effect of different sympathetic stimuli-autonomic dysreflexia and head-up tilt-on leg vascular resistance in spinal cord injury. Arch Phys Med Rehabil 2010 0.76
56 NT5E mutations and arterial calcifications. N Engl J Med 2011 0.75
57 Effect of the 34C>T variant in the AMPD1 gene on the clinical response to methotrexate in patients with rheumatoid arthritis: comment on the article by Wessels et al. Arthritis Rheum 2007 0.75
58 The nonspecific anti-inflammatory therapy with methotrexate for patients with chronic heart failure. Am Heart J 2006 0.75
59 Caffeine and coffee tolerance. Circulation 2003 0.75
60 Reflex systemic sympatho-neural response to brachial adenosine infusion in treated heart failure. Eur J Heart Fail 2011 0.75
61 Reduced adenosine receptor stimulation as a pathogenic factor in hyperhomocysteinemia. Clin Chem Lab Med 2005 0.75
62 Plasma galectin-3 concentrations in patients with primary aldosteronism. J Hypertens 2017 0.75
63 The effect of remote ischemic preconditioning on exercise-induced plasma troponin I appearance in healthy volunteers. Int J Cardiol 2013 0.75
64 A randomised trial on the effect of anti-platelet therapy on the systemic inflammatory response in human endotoxaemia. Thromb Haemost 2017 0.75
65 The role of myocardial KATP-channel blockade in the protective effects of glibenclamide against ischaemia in the rat heart. Pharmacol Toxicol 2002 0.75
66 Sunitinib does not attenuate contractile force following a period of ischemia in isolated human cardiac muscle. Target Oncol 2014 0.75